中华病理学杂志
中華病理學雜誌
중화병이학잡지
Chinese Journal of Pathology
2009年
1期
42-46
,共5页
范丽昕%沈琳%李吉友%潘凯枫%董彬%张阳
範麗昕%瀋琳%李吉友%潘凱楓%董彬%張暘
범려흔%침림%리길우%반개풍%동빈%장양
胰腺肿瘤%Kangai-1蛋白质%杂合性丢失%转移%预后
胰腺腫瘤%Kangai-1蛋白質%雜閤性丟失%轉移%預後
이선종류%Kangai-1단백질%잡합성주실%전이%예후
Pancreatic neoplasms%Kangai-1 protein%Loss of heterozygosity%Metastasis%Prognosis
目的 探讨肿瘤转移抑制基因KAI1与胰腺癌转移及预后的相关性,并进一步研究此相关性与其等位基因杂合性缺失(LOH)的关系.方法 收集胰腺癌标本62例,行免疫组织化学Power-vision二步法检测KAI1基因(CD82)的表达;石蜡切片显微切割癌及癌旁正常胰腺组织,提取DNA,变性高效液相色谱法(DHPLC)检测LOH.结果 CD82在胰腺癌原发灶中表达率为76%(47/62),在有淋巴结转移、远处脏器转移病例中表达显著降低(P<0.05),在晚期(Ⅲ、Ⅳ)肿瘤中比早期(Ⅰ、Ⅱ)表达显著降低(P<0.01),CD82表达阳性者的1年生存率显著高于表达阴性者(P<0.05).显微切割标本PCR扩增,微卫星D11S1344有5对、D11S1326有2对存在LOH,发生率为17%.结论 随着胰腺癌的进展,CD82的表达逐渐降低,这种降低与KAI1等位基因的杂合性缺失有关.检测CD82的表达及LOH对判断肿瘤的分期,淋巴转移和远处转移及患者的预后有一定的参考价值.
目的 探討腫瘤轉移抑製基因KAI1與胰腺癌轉移及預後的相關性,併進一步研究此相關性與其等位基因雜閤性缺失(LOH)的關繫.方法 收集胰腺癌標本62例,行免疫組織化學Power-vision二步法檢測KAI1基因(CD82)的錶達;石蠟切片顯微切割癌及癌徬正常胰腺組織,提取DNA,變性高效液相色譜法(DHPLC)檢測LOH.結果 CD82在胰腺癌原髮竈中錶達率為76%(47/62),在有淋巴結轉移、遠處髒器轉移病例中錶達顯著降低(P<0.05),在晚期(Ⅲ、Ⅳ)腫瘤中比早期(Ⅰ、Ⅱ)錶達顯著降低(P<0.01),CD82錶達暘性者的1年生存率顯著高于錶達陰性者(P<0.05).顯微切割標本PCR擴增,微衛星D11S1344有5對、D11S1326有2對存在LOH,髮生率為17%.結論 隨著胰腺癌的進展,CD82的錶達逐漸降低,這種降低與KAI1等位基因的雜閤性缺失有關.檢測CD82的錶達及LOH對判斷腫瘤的分期,淋巴轉移和遠處轉移及患者的預後有一定的參攷價值.
목적 탐토종류전이억제기인KAI1여이선암전이급예후적상관성,병진일보연구차상관성여기등위기인잡합성결실(LOH)적관계.방법 수집이선암표본62례,행면역조직화학Power-vision이보법검측KAI1기인(CD82)적표체;석사절편현미절할암급암방정상이선조직,제취DNA,변성고효액상색보법(DHPLC)검측LOH.결과 CD82재이선암원발조중표체솔위76%(47/62),재유림파결전이、원처장기전이병례중표체현저강저(P<0.05),재만기(Ⅲ、Ⅳ)종류중비조기(Ⅰ、Ⅱ)표체현저강저(P<0.01),CD82표체양성자적1년생존솔현저고우표체음성자(P<0.05).현미절할표본PCR확증,미위성D11S1344유5대、D11S1326유2대존재LOH,발생솔위17%.결론 수착이선암적진전,CD82적표체축점강저,저충강저여KAI1등위기인적잡합성결실유관.검측CD82적표체급LOH대판단종류적분기,림파전이화원처전이급환자적예후유일정적삼고개치.
Objective To investigate the role of KAI1 gene expression and loss of heterozygosity (LOH) of KAI1 in metastatic potential and prognosis of pancreatic cancer. Methods The expression of KAI1 gene was studied by immunohistochemistry for CD82 on paraffin-embedded tumor tissues. The LOH of KAI1 gene was detected by microdissection, polymerase chain reaction (PCR) and denaturing high performance liquid chromatography (DHPLC). Results The pesitivity rate of CD82 in primary pancreatic cancer was 76% (47/62). CD82 expression was significantly higher (P<0.01 ) in earlier tumor stages (Ⅰ and Ⅱ), as compared to the advanced tumor stages (Ⅲ and Ⅳ) in which nodal or distant metastases were present. The expression rate of CD82 in patients who survived for more than one year was higher than that in patients who survived for less than one year ( P<0.05 ). The percentage of LOH at D11S1344 and D11S1326 loci was 17%. Conclusions The abnormal expression of CD82 which participates in malignant progression of pancreatic cancer is probably associated with LOH of KAI1 gene. Detection of CD82 expression and LOH of KAI1 gene may carry potential clinical significance in evaluating the metastatic potential and prognosis of pancreatic cancer.
